Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu

  • Daiichi Sankyo Co Ltd DSKYF and AstraZeneca plc AZN have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.
  • The primary endpoint of the trial is overall survival. 
  • Secondary endpoints include investigator-assessed progression-free survival, objective response rate, duration of response, disease control rate, safety, pharmacokinetics, and immunogenicity.
  • The study will enroll approximately 490 patients.
  • Price Action: AZN shares are down 1.15% at $59.08 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsstomach cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!